Glyoxalase in tumourigenesis and multidrug resistance

Seminars in Cell and Developmental Biology

Volumn 22, Issue 3, 2011, Pages 318-325

  Thornalley, Paul J ^a   Rabbani, Naila ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Cancer; DNA damage; Gene amplification; Methylglyoxal; Multidrug resistance

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CISPLATIN; DOXORUBICIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GLYOXALASE; HYDROXYACYLGLUTATHIONE HYDROLASE; LACTIC ACID; LACTOYLGLUTATHIONE LYASE; METHYLGLYOXAL; MITOMYCIN C; NUCLEOTIDE; PHOSPHOLIPID; PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CELL VIABILITY; COLON CANCER; CYTOTOXICITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GENE AMPLIFICATION; GLYCATION; GLYCOGENOLYSIS; GLYCOLYSIS; HUMAN; LEUKEMIA; LIVER CELL CARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; MALIGNANT TRANSFORMATION; MULTIDRUG RESISTANCE; NONHUMAN; OVARY CANCER; OXIDATIVE STRESS; PANCREAS CANCER; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; STOMACH CANCER; TUMOR CELL; TUMOR GROWTH;

EID: 79955945922     PISSN: 10849521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcdb.2011.02.006     Document Type: Review

References (83)

1. Xue M., Rabbani N., Thornalley P.J. Glyoxalase in ageing. Semin Cell Dev Biol 2011, 22:293-301.
2. Dakin H.D., Dudley H.W. An enzyme concerned with the formation of hydroxy acids from ketonic aldehydes. J Biol Chem 1913, 14:155-157.
3. Neuberg C. The destruction of lactic aldehyde and methylglyoxal by animal organs. Biochem Z 1913, 49:502-506.
4. Warburg O. Metabolism of tumours. Biochem Z 1923, 142:317-333.
5. Racker E. The mechanism of action of glyoxalase. J Biol Chem 1951, 190:685-696.
6. Racker E. Glutathione as coenzyme in intermediary metabolism. Glutathione 1954, 208. Academic Press, New York. S. Colowick, A. Lazarow, E. Racker, D.R. Schwarz, E. Stadtman, H. Waelsch (Eds.).
7. Ekwall K., Mannervik B. The stereochemical configuration of the lactoyl group of S-lactoylglutathione formed by the action of glyoxalase I from porcine erythrocytes and yeast. Biochim Biophys Acta 1973, 297:297-299.
8. Platt M.E., Schroeder E.F. Glyoxalase: II. The distribution of glyoxalase in tissues of normal and cancerous albino rats. J Biol Chem 1934, 106:179-190.
9. Jowett M., Quastel J.H. The glyoxalase activity of tissues. Biochem J 1934, 28:162-172.
10. 32P-postlabelling technique for the analysis of 2'-deoxyguanosine-3'-monophosphate and DNA of methylglyoxal. Carcinogenesis 1994, 15:1887-1894.
11. Szent-Gyorgyi A., Egyud L.G., McLaughlin J.A. Keto-aldehyde and cell division. Science 1967, 155:539-541.
12. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
13. Apple M.A., Greenberg D.M. Arrest of cancer in mice by therapy with normal metabolites. I. 2-Oxopropanal (NSC-79019). Cancer Chemother Rep 1967, 51:455-464.
14. Vince R., Wadd W.B. Glyoxalase inhibitors as potential anticancer agents. Biochem Biophys Res Commun 1969, 35:593-598.
15. Jerzykowski T., Winter R., Matuszewski W., Szczurek Z. Glyoxalase II activity in tumours. Cell Mol Life Sci 1975, 31:32-33.
16. Jerzykowski T., Winter R., Matuszewski W., Piskorska D. A re-evaluation on the distribution of glyoxalases in animal and tumor tissues. Int J Biochem 1978, 9:853-860.
17. Lo T.W.C., Thornalley P.J. Inhibition of proliferation of human leukemia 60 cells by diethyl esters of glyoxalase inhibitors in vitro. Biochem Pharmacol 1992, 44:2357-2363.
18. Thornalley P.J., Edwards L.G., Kang Y., Wyatt C., Davies N., Ladan M.J., et al. Antitumour activity of S-p-bromobenzylglutathione cyclopentyl diester in vitro and in vivo. Inhibition of glyoxalase I and induction of apoptosis. Biochem Pharmacol 1996, 51:1365-1372.
19. Zheng Z.B., Creighton D.J. Bivalent transition-state analogue inhibitors of human glyoxalase I. Org Lett 2003, 5:4855-4858.
20. More S.S., Vince R. Inhibition of glyoxalase I: the first low-nanomolar tight-binding inhibitors. J Med Chem 2009, 52:4650-4656.
21. Tanabe Y., Kitahara-Tanabe N., Mizuno D., Soma G.-I. Enhanced production of tumour necrosis factor α (TNF α) by its precursor on the cell surface of primed THP-1 cells. Cytokine 1994, 6:337-348.
22. Sakamoto H., Mashima T., Sato S., Hashimoto Y., Yamori T., Tsuruo T. Selective activation of apoptosis program by S-p-bromobenzylglutathione cyclopentyl diester in glyoxalase I-overexpressing human lung cancer cells. Clin Cancer Res 2001, 7:2513-2518.
23. Sejersen H., Rattan S. Dicarbonyl-induced accelerated aging in vitro in human skin fibroblasts. Biogerontology 2009, 10:203-211.
24. Young T.W., Mei F.C., Yang G., Thompson-Lanza J.A., Liu J., Cheng X. Activation of antioxidant pathways in Ras-mediated oncogenic transformation of human surface ovarian epithelial cells revealed by functional proteomics and mass spectrometry. Cancer Res 2004, 64:4577-4584.
25. Yang Y.X., Chen Z.C., Zhang G.Y., Yi H., Xiao Z.Q. A subcelluar proteomic investigation into vincristine-resistant gastric cancer cell line. J Cell Biochem 2008, 104:1010-1021.
26. Thornalley P.J. The glyoxalase system in health and disease. Mol Aspects Med 1993, 14:287-371.
27. Phillips S.A., Thornalley P.J. The formation of methylglyoxal from triose phosphates. Investigation using a specific assay for methylglyoxal. Eur J Biochem 1993, 212:101-105.
28. Thornalley P.J. Modification of the glyoxalase system in human red blood cells by glucose in vitro. Biochem J 1988, 254:751-755.
29. 1 growth arrest and induction of apoptosis. Leuk Res 1996, 20:397-405.
30. Thornalley P.J. Glyoxalase I - structure, function and a critical role in the enzymatic defence against glycation. Biochem Soc Trans 2003, 31:1343-1348.
31. Thornalley P.J. The enzymatic defence against glycation in health, disease and therapeutics: a symposium to examine the concept. Biochem Soc Trans 2003, 31:1343-1348.
32. Ahmed N., Argirov O.K., Minhas H.S., Cordeiro C.A., Thornalley P.J. Assay of advanced glycation endproducts (AGEs): surveying AGEs by chromatographic assay with derivatisation by aminoquinolyl-N-hydroxysuccimidyl-carbamate and application to Ne{open}-carboxymethyl-lysine- and Ne{open}-(1-carboxyethyl)lysine-modified albumin. Biochem J 2002, 364:1-14.
33. Rabbani N, Thornalley PJ. Methylglyoxal, glyoxalase 1 and the dicarbonyl proteome. Amino Acids, in press.
34. Thornalley P.J., Waris S., Fleming T., Santarius T., Larkin S.J., Winklhofer-Roob B.M., et al. Imidazopurinones are markers of physiological genomic damage linked to DNA instability and glyoxalase 1-associated tumour multidrug resistance. Nucleic Acids Res 2010, gkq306.
35. Shoji N., Nakagawa K., Asai A., Fujita I., Hashiura A., Nakajima Y., et al. LC-MS/MS analysis of carboxymethylated and carboxyethylated phosphatidylethanolamines in human erythrocytes and blood plasma. J Lipid Res 2010, 51:2445-2453.
36. Thornalley P.J., Battah S., Ahmed N., Karachalias N., Agalou S., Babaei-Jadidi R., et al. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J 2003, 375:581-592.
37. Dobler D., Ahmed N., Song L.J., Eboigbodin K.E., Thornalley P.J. Increased dicarbonyl metabolism in endothelial cells in hyperglycemia induces anoikis and impairs angiogenesis by RGD and GFOGER motif modification. Diabetes 2006, 55:1961-1969.
38. Thornalley P.J. Protein and nucleotide damage by glyoxal and methylglyoxal in physiological systems - role in ageing and disease. Drug Metab Drug Interact 2008, 23:125-150.
39. Chan W.H., Wu H.J., Shiao N.H. Apoptotic signaling in methylglyoxal-treated human osteoblasts involves oxidative stress, c-jun N-terminal kinase, caspase-3, and p21-activated kinase 2. J Cell Biochem 2007, 100:1056-1069.
40. Ayoub F.M., Allen R.E., Thornalley P.J. Inhibition of proliferation of human leukaemia 60 cells by methylglyoxal in vitro. Leuk Res 1993, 17:397-401.
41. Vandenabeele P., Galluzzi L., Vanden Berghe T., Kroemer G. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol 2010, 11:700-714.
42. Gatenby R.A., Gillies R.J. Why do cancers have high aerobic glycolysis?. Nat Rev Cancer 2004, 4:891-899.
43. Tennant D.A., Duran R.V., Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 2010, 10:267-277.
44. Santarius T., Bignell G.R., Greenan C.D., Widaa S., Chen L., Mahoney C.L., et al. GLO1 - a novel amplified gene in human cancer. Genes Chromsomes Cancer 2010, 49:711-725.
45. Ranganathan S., Walsh E.S., Tew K.D. Glyoxalase I in detoxification: studies using a glyoxalase I transfectant cell line. Biochem J 1995, 309:127-131.
46. Sakamoto H., Mashima T., Kazaki A., Dan S., Hashimoto Y., Naito M., et al. Glyoxalase I is involved in resistance of human leukemia cells to antitumour agent-induced apoptosis. Blood 2000, 95:3214-3218.
47. Ronen S.M., DiStefano F., McCoy C.L., Robertson D., Smith T.A.D., Al-Saffar N.M., et al. Magnetic resonance detects metabolic changes associated with chemotherapy-induced apoptosis. Brit J Cancer 1999, 80:1035-1041.
48. Hara M.R., Agrawal N., Kim S.F., Cascio M.B., Fujimuro M., Ozeki Y., et al. S-nitrosylated GAPDH initiates apoptotic cell death by nuclear translocation following Siah1 binding. Nat Cell Biol 2005, 7:665-740.
49. Lautier D., Lagueux J., Thibodeau J., Menard L., Poirier G.G. Molecular and biochemical features of poly(ADP-ribose) metabolism. Mol Cell Biochem 1993, 122:171-193.
50. 2-induced block of glycolysis as an active ADP-ribosylation reaction protecting cells from apoptosis. FASEB J 2000, 14:2266-2276.
51. Zhou R., Vander Heiden M.G., Rudin C.M. Genotoxic exposure is associated with alterations in glucose uptake and metabolism. Cancer Res 2002, 62:3515-3520.
52. Hosking L.K., Whelan R.D.H., Shellard S.A., Bedford P., Hill B.T. An evaluation of the role of glutathione and its associated enzymes in the expression of differential sensitivities to antitumor agents shown by a range of human tumor-cell lines. Biochem Pharmacol 1990, 40:1833-1842.
53. Abordo E.A., Minhas H.S., Thornalley P.J. Accumulation of α-oxoaldehydes during oxidative stress. A role in cytotoxicity. Biochem Pharmacol 1999, 58:641-648.
54. Mitsumoto A., Kim K.R., Oshima G., Kunimoto M., Okawa K., Iwamatsu A., et al. Glyoxalase I is a novel nitric-oxide-responsive protein. Biochem J 1999, 344:837-844.
55. Birkenmeier G., Stegemann C., Hoffmann R., Gunther R., Huse K., Birkemeyer C. Posttranslational modification of human glyoxalase 1 indicates redox-dependent regulation. PLoS One 2010, 5:e10399.
56. Grander D., Panaretakis T. Autophagy: cancer therapy's friend or foe?. Future Med Chem 2010, 2:285-297.
57. Kristensen A.R., Schandorff S., Hoyer-Hansen M., Nielsen M.O., Jaattela M., Dengjel J., et al. Ordered organelle degradation during starvation-induced autophagy. Mol Cell Proteomics 2008, 7:2419-2428.
58. Speer O., Morkunaite-Haimi S., Liobikas J., Franck M., Hensbo L., Linder M.D., et al. Rapid suppression of mitochondrial permeability transition by methylglyoxal. J Biol Chem 2003, 278:34757-34763.
59. Godbout J.P., Pesavento J., Hartman M.E., Manson S.R., Freund G.G. Methylglyoxal enhances cisplatin-induced cytotoxicity by activating protein kinase C delta. J Biol Chem 2002, 277:2554-2561.
60. Yoshida K., Wang H.G., Miki Y., Kufe D. Protein kinase C delta is responsible for constitutive and DNA damage-induced phosphorylation of Rad9. EMBO J 2003, 22:1431-1441.
61. Xu Y., Chen X. Glyoxalase II, a detoxifying enzyme of glycolysis byproduct methylglyoxal and a target of p63 and p73, is a pro-survival factor of the p53 family. J Biol Chem 2006, 281:26702-26713.
62. Schraml P., Kononen J., Bubendorf L., Moch H., Bissig H., Nocito A., et al. Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 1999, 5:1966-1975.
63. Belloir C., Singh V., Daurat C., Siess M.H., Le Bon A.M. Protective effects of garlic sulfur compounds against DNA damage induced by direct- and indirect-acting genotoxic agents in HepG2 cells. Food Chem Toxicol 2006, 44:827-834.
64. Song H.Y., Liu Y.K., Feng J.T., Cui J.F., Dai Z., Zhang L.J., et al. Proteomic analysis on metastasis-associated proteins of human hepatocellular carcinoma tissues. J Cancer Res Clin Oncol 2006, 132:92-98.
65. Nakamura T., Furukawa Y., Nakagawa H., Tsunoda T., Ohigashi H., Murata K., et al. Genome-wide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection. Oncogene 2004, 23:2385-2400.
66. Bartyik K., Turi S., Orosz F., Karg E. Methotrexate inhibits the glyoxalase system in vivo in children with acute lymphoid leukaemia. Eur J Cancer 2004, 40:2287-2292.
67. Vince R., Daluge S., Wadd W.B. Studies on the inhibition of glyoxalase I by S-substituted glutathione. J Med Chem 1971, 14:402-404.
68. Murthy N.S.R.K., Bakeris T., Kavarana M.J., Hamilton D.S., Lan Y., Creighton D.J. S-(N-aryl-N-hydroxycarbamoyl)glutathione derivatives are tight-binding inhibitors of glyoxalase-I and Slow substrates for glyoxalase-Ii. J Med Chem 1994, 37:2161-2166.
69. Sharkey E.M., O'Neill H.B., Kavarana M.J., Wang H.B., Creighton D.J., Sentz D.L., et al. Pharmacokinetics and antitumor properties in tumor-bearing mice of an enediol analogue inhibitor of glyoxalase I. Cancer Chemother Pharmacol 2000, 46:156-166.
70. Kavarana M.J., Kovaleva E.G., Creighton D.J., Wollman M.B., Eiseman J.L. Mechanism-based competitive inhibitors of glyoxalase I: intracellular delivery, in vitro antitumor activities, and stabilities in human serum and mouse serum. J Med Chem 1999, 42:221-228.
71. Santel T., Pflug G., Hemdan N.Y.A., Schafer A., Hollenbach M., Buchold M., et al. Curcumin inhibits glyoxalase 1: a possible link to its anti-inflammatory and anti-tumor activity. PLoS One 2008, 3.
72. Takeuchi M., Kimura S., Kuroda J., Ashihara E., Kawatani M., Osada H., et al. Glyoxalase-I is a novel target against Bcr-Abl(+) leukemic cells acquiring stem-like characteristics in a hypoxic environment. Cell Death Diff 2010, 17:1211-1220.
73. Takeuchi M., Kimura S., Kuroda J., Ashihara E., Kawatani M., Osada H., et al. Hypoxia-adapted CML cells are more primitive population and are eradicated by glyoxalase-1 inhibitors. Blood 2009, 114:852-853.
74. Mearini E., Romani R., Mearini L., Antognelli C., Zucchi A., Baroni T., et al. Differing expression of enzymes of the glyoxalase system in superficial and invasive bladder carcinomas. Eur J Cancer 2002, 38:1946-1950.
75. Rulli A., Carli L., Romani R., Baroni T., Giovannini E., Rosi G., et al. Expression of glyoxalase I and II in normal and breast cancer tissues. Breast Cancer Res Treat 2001, 66:72.
76. Zhang D., Tai L.K., Wong L.L., Chiu L.L., Sethi S.K., Koay E.S.C. Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol Cell Proteomics 2005, 4:1686-1696.
77. Ranganathan S., Tew K.D. Analysis of glyoxalase I from normal and tumour tissue from human colon. Biochim Biophys Acta 1994, 1170:17-24.
78. Cui J.W., Wang J., He K., Jin B.F., Wang H.X., Li W., et al. Proteomic analysis of human acute leukemia cells: insight into their classification. Clin Cancer Res 2004, 10:6887-6896.
79. Hooper N.I., Tisdale M.J., Thornalley P.J. Modification of the glyoxalase system in human HL60 promyelocytic leukaemia cells during differentiation to neutrophils in vitro. Biochim Biophys Acta 1988, 966:362-369.
80. Amatschek S., Koenig U., Auer H., Steinlein P., Pacher M., Gruenfelder A., et al. Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. Cancer Res 2004, 64:844-856.
81. Jones M.B., Krutzsch H., Shu H., Zhao Y., Liotta L.A., Kohn E.C., et al. Proteomic analysis and identification of new biomarkers antherpaeutic agents for invasive ovarian cancer. Proteomics 2002, 2:78-84.
82. Davidson S.D., Cherry J.P., Choudhury M.S., Tazaki H., Mallouh C., Konno S. Glyoxalase I activity in human prostate cancer: a potential marker and importance in chemotherapy. J Urol 1999, 161:690-691.
83. Allen R.E., Lo T.W.C., Thornalley P.J. A simplified method for the purification of human red blood cell glyoxalase I. Characteristics, immunoblotting and inhibitor studies. J Prot Chem 1993, 12:111-119.